HopeStage
Back to all studies
CompletedNCT00992407

Long-acting injection or tablets of risperidone for schizophrenia

About this titleRead the official source — NCT00992407
Medication studyAges 18–55South Korea
The study in practice

Understand this study

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.

Get this study by email

HopeStage may email me about this study.
Loading the security check...
Study clarity

Study information

Study start dateDecember 2007
Recruitment status
Completed
Enrollment listed in the registry
75
Sponsor
Janssen Korea, Ltd., Korea
Sponsor type
Other organization
Study type
Drug
Intervention type
Medication / drug
Study phase
Phase 4Usually happens after approval, to monitor real-world use, safety, and longer-term outcomes.
Locations
South Korea
Age range
From 18 Years to 55 Years
Official registry ID
NCT00992407
Official title
Show the full official title

A Randomized, Open-label, Active-controlled Study to Evaluate Social Functioning of Long Acting Injectable Risperidone and Oral Risperidone in the Treatment of Subjects With Schizophrenia or Schizoaffective Disorder

Looking for a study you can join?

Explore recruiting studies

Recruitment & locations

Completed

Ansan

FAQ

Questions about this study

Who is behind this study?

The study sponsor is Janssen Korea, Ltd., Korea.

Did this study involve medication?

Yes. The study involved medication, including Risperidone long acting injectables and Risperidone tablets.

Who was this study for?

This study was for people with schizophrenia. Listed age limits: 18 years to 55 years. Other eligibility criteria applied.

Want to explore more studies?

Explore studies